Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
REGN Analyst Ratings
Strong Buy
16 Buy
3 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
REGN Stock 12 Month Forecast
Average Price Target
$958.60
▲(39.81% Upside)
| Highest Price Target$1,182 | Average Price Target$958.60 | Lowest Price Target$575.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Guggenheim
Reiterated
02/11/25
Evercore ISI
Reiterated
02/07/25
Leerink Partners
Upgraded
02/06/25
Bank of America Securities
Reiterated
02/05/25
Truist Financial
Reiterated
02/05/25
Oppenheimer
Reiterated
02/05/25
Robert W. Baird
Reiterated
02/05/25
Morgan Stanley
Reiterated
02/04/25
Wells Fargo
Reiterated
02/04/25
RBC Capital
$1,059→$1,045
Buy
52.41%
Upside
Reiterated
02/04/25
RBC Capital Reaffirms Their Buy Rating on Regeneron (REGN)
TD Cowen
$1,030→$970
Buy
41.47%
Upside
Reiterated
02/04/25
Regeneron Stock: Buy Rating Backed by Robust Growth Prospects and Strategic Financial Moves
Goldman Sachs
$1,185→$1,182
Buy
72.39%
Upside
Reiterated
02/03/25
Regeneron: Buy Rating Amidst Challenges and Opportunities for GrowthWe see upside potential per execution on favorable near-term Eylea HD label-enhancing catalysts and the pipeline (including obesity, thrombosis, severe food allergy, and oncology, among others) albeit recognize risks. On the 4Q earnings report, we look to management commentary on Eylea 2mg trough levels to address the wide range of Street estimates (FY25 US company-compiled consensus range of $2.1-$4.0bn for Eylea franchise) which could remove an overhang if provided. REGN’s US Eylea franchise accounts for ~42% of REGN’s sales (as of FY24) and treats the largest retinal disease market: wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR).
Jefferies
$1,120
Buy
63.35%
Upside
Reiterated
02/03/25
Jefferies Sticks to Their Buy Rating for Regeneron (REGN)
Canaccord Genuity
$1,152
Buy
68.01%
Upside
Reiterated
02/03/25
Regeneron Buy Rating: Anticipated Catalysts and Diversification Drive Growth PotentialWe believe EYLEA revenue will continue to be pressured in 1H25, due to heavy competition - we await commentary on REGN's 4Q24 call on 2/4. During pre-release at JPM, Regeneron reported lower-than-expected $1,495M total US EYLEA (HD+2mg) for 4Q24,including $305M for EYLEA HD vs $392M in 3Q24. In addition, Regeneron noted a +$85M favorable inventory impact for combined EYLEA+EYLEA HD in 4Q24. In addition, we look for detail on biosimilar competition from Amgen's Pavblu (EYLEA 2mg biosimilar), launched at risk in 3Q24.
Best Analysts Covering Regeneron
Which Analyst Should I Follow If I Want to Buy REGN and Sell After:
1 Month
xxx
Success Rate
17/28 ratings generated profit
Average Return
+1.71%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.71% of your transactions generating a profit, with an average return of +1.71% per trade.
3 Months
xxx
Success Rate
17/28 ratings generated profit
Average Return
+2.51%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.71% of your transactions generating a profit, with an average return of +2.51% per trade.
1 Year
Success Rate
29/42 ratings generated profit
Average Return
+15.74%
assigned a buy rating 23 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 69.05% of your transactions generating a profit, with an average return of +15.74% per trade.
2 Years
xxx
Success Rate
13/19 ratings generated profit
Average Return
+15.16%
upgraded a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 68.42% of your transactions generating a profit, with an average return of +15.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
REGN Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
1
2
7
17
20
Buy
56
52
31
21
17
Hold
8
10
9
11
9
Sell
1
2
2
3
3
Strong Sell
0
0
0
0
0
total
66
66
49
52
49
Each month's total comprises the sum of three months' worth of ratings.
REGN Financial Forecast
REGN Stock Forecast FAQ
What is REGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Regeneron’s 12-month average price target is $958.60.
What is REGN’s upside potential, based on the analysts’ average price target?
Regeneron has 39.81% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is REGN a Buy, Sell or Hold?
Regeneron has a consensus rating of Strong Buy which is based on 16 buy ratings, 3 hold ratings and 1 sell ratings.
What is Regeneron’s price target?
The average price target for Regeneron is $958.60. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,182.00 ,the lowest forecast is $575.00. The average price target represents 39.81% Increase from the current price of $685.66.
The highest analyst price target is $1,182.00 ,the lowest forecast is $575.00. The average price target represents 39.81% Increase from the current price of $685.66.
What do analysts say about Regeneron?
Regeneron’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
How can I buy shares of REGN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.